One embodiment of an aspect of the present invention is a method for lessening the symptoms of depression anxiety and post-traumatic stress disorder comprising the step of administering a therapeutically effective quantity of a cholinergic M1 receptor antagonist and a therapeutically effective quantity of one or more cholinomimetic agents to lessen the symptoms of depression anxiety and post-traumatic stress disorder. Typically the cholinergic M1 receptor antagonist is selected from the group co...

Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more muscarinic antagonist compounds. Examples of muscarin ic antagonists utilized in the pharmaceutical composition and method of treatment are 10H-thieno(34-b)(15)benzodiazepin - 10-one 49-dihydro-3-methyl-4-((4-methyl-1-piperazinyl) acetyl...

Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more muscarinic antagonist compounds. Examples of muscarinic antagonists utilized in the pharmaceutical composition and method of treatment are: 10H-thieno(34-b)(15)benzodiazepin-10-one 49-dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl) (...

This invention discloses that a combination of two drugs from two different and unrelated categories provides effective and long-lasting relief from neuropathic pain. Both drugs can be taken orally in a convenient painless non-invasive manner that does not require injections. One drug is an aryl-cyclo-alkanolamine (ACAA) which has antagonist (receptor-blocking) activity at the NMDA subclass of glutamate receptors; such drugs include procyclidine biperiden and trihexyphenidyl. The other drug is a...